Myosin Therapeutics, a clinical stage biotechnology company developing therapies for oncology, announced on Tuesday that the first patient has been dosed in the Phase 1/2 STAR-GBM study of its lead programme, MT-125.

MT-125 is a first-in-class inhibitor of non-muscle myosin II (NMII), designed to disrupt the physical mechanics of tumour cells to induce tumour cell collapse and death through non-redundant mechanisms distinct from any existing therapy.

The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary signals of clinical activity with longitudinal imaging in adults with newly diagnosed glioblastoma (GBM). With support from the National Cancer Institute (NCI/NIH), the trial is being conducted in collaboration with the Mayo Clinic across its Minnesota, Florida, and Arizona campuses.

MT-125 has received Orphan Drug Designation for malignant gliomas and Fast Track Designation for glioblastoma, supporting an accelerated regulatory pathway. In addition to GBM, MT-125 is being developed for other treatment-resistant cancers, including acute myeloid leukaemia and pancreatic cancer.